GEN Exclusives

More »

GEN News Highlights

More »
Mar 23, 2007

Procognia Supplies Protein Kinase Arrays to GlaxoSmithKline

  • Procognia entered into a collaboration with GlaxoSmithKline to explore the use of Procognia’s protein function arrays within the GSK drug development processes in combination with GSK’s fluorescently-labeled, broad-specificity kinase inhibitors.

    Under the collaboration, Procognia will be supplying arrays, which contain over 300 functional human kinases, to GSK to enable it to profile its kinase hits in-house. The arrays allow researchers to profile many kinases in a single parallel experiment where previously many separate assays were required.

    In addition, Procognia and GSK will work together to assess where Procognia’s protein array technology can be integrated into GSK’s screening process.

    Overexpression and misregulation of protein kinases are implicated in a wide variety of diseases. As a result, researchers are developing drugs that alter the activity of targeted kinases in areas such as cancer, inflammation, heart disease, and neuro-degenerative diseases. Across the industry, 30% of all drug discovery efforts are now focused on targeting protein kinases.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?